Thu, Jul 10, 2014, 11:27 AM EDT - U.S. Markets close in 4 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • wildbullus wildbullus May 17, 2013 6:37 PM Flag

    z944 P1 MAD completed in late 2012

    Z944 Presented at the American Pain Society 2013 Annual Meeting

    Z944 is a novel, oral, state-dependent, selective T-type calcium channel blocker that has demonstrated preclinical efficacy in multiple inflammatory pain models. T-type calcium channels have been recognized as key targets for therapeutic intervention in a broad range of cell functions and have been implicated in pain signaling. Zalicus completed Phase 1 single and multiple ascending dose clinical studies evaluating the safety and tolerability of Z944 in late 2012 and plans to continue further clinical development during 2013.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ZLCS
1.16-0.020(-1.69%)11:23 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.